Quick Answer
Processa Pharmaceuticals, Inc. reported Operating Income of -$13.99 million for fiscal year 2025.
Processa Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$13.99M | -16.1% |
| 2024 | -$12.05M | -5.2% |
| 2023 | -$11.46M | +58.4% |
| 2022 | -$27.53M | -126.9% |
| 2021 | -$12.13M | +19.8% |
| 2020 | -$15.14M | -284.6% |
| 2019 | -$3.94M | +13.0% |
| 2018 | -$4.52M | -151.0% |
| 2017 | -$1.80M | +6.2% |
| 2016 | -$1.92M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.49M | -1.9% | +11.7% |
| June 30, 2025 | -$3.95M | -28.2% | -38.8% |
| March 31, 2025 | -$2.85M | -1.3% | +16.9% |
| September 30, 2024 | -$3.42M | -58.0% | -11.1% |
| June 30, 2024 | -$3.08M | -13.5% | -9.7% |
| March 31, 2024 | -$2.81M | +31.6% | -29.6% |
| September 30, 2023 | -$2.17M | +64.2% | +20.1% |
| June 30, 2023 | -$2.71M | +47.5% | +33.9% |
- Processa Pharmaceuticals, Inc. showed a decrease of -16.1% in Operating Income compared to the prior fiscal year.
- Over the 2016–2025 period, Processa Pharmaceuticals, Inc.’s operating income has declined by 628.0% (from -$1.92 million to -$13.99 million).
- The most recent figure is from Processa Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: